Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is the first of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
Clinical studies from 2025 show that post-surgical patients lose an average of 13.5% additional body weight when using GLP-1 agonists
If you want to learn more about the side effects and safety of drugs like Ozempic and Wegovy, see our article here
Medicines and Healthcare Regulatory Agency (MHRA) (2026) GLP-1 medicines for weight loss and diabetes: what you need to know, GOV.UK
Growth is also driven by the rise of telehealth consultations and digital prescriptions, enabling easier patient access to GLP-1 therapies without visiting physical stores
US$ 27.44
US$ 28.26
US$ 27.28
